Beyond the scavenging of reactive oxygen species (ROS): direct efect of cerium oxide nanoparticles in reducing fatty acids content in an in vitro model of hepatocellular steatosis

dc.contributor
[Parra-Robert M, Massana N, Perramón M] Service of Biochemistry and Molecular Genetics, Hospital Clinic Universitari, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Madrid, Spain. [Casals E, Zeng M] School of Biotechnology and Health Sciences, Wuyi University, Jiangmen, China. [Fernández-Varo G] Service of Biochemistry and Molecular Genetics, Hospital Clinic Universitari, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Madrid, Spain. Departament of Biomedicine, University of Barcelona, Barcelona, Spain. [Puntes V] Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Institut Català de Nanociència i Nanotecnologia (ICN2), CSIC, The Barcelona Institute of Science and Technology (BIST), Universitat Autònoma de Barcelona, Bellaterra, Spain. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Parra-Robert, Marina
dc.contributor.author
Massana Martinell, Nuria
dc.contributor.author
Zeng, Muling
dc.contributor.author
Perramón, Meritxell
dc.contributor.author
Fernández-Varo, Guillermo
dc.contributor.author
Franco Puntes, Victor
dc.contributor.author
Casals, Eudald
dc.date.accessioned
2025-10-24T08:50:57Z
dc.date.available
2025-10-24T08:50:57Z
dc.date.issued
2020-03-10T12:49:28Z
dc.date.issued
2020-03-10T12:49:28Z
dc.date.issued
2019-08-29
dc.identifier
Parra-Robert M, Casals E, Massana N, Zeng M, Perramón M, Fernández-Varo G, et al. Beyond the scavenging of reactive oxygen species (ROS): direct effect of cerium oxide nanoparticles in reducing fatty acids content in an in vitro model of hepatocellular steatosis. Biomolecules. 2019 Aug 29;9(9):e425.
dc.identifier
2218-273X
dc.identifier
https://hdl.handle.net/11351/4721
dc.identifier
10.3390/biom9090425
dc.identifier
31470518
dc.identifier
000489102800037
dc.identifier.uri
http://hdl.handle.net/11351/4721
dc.description.abstract
Cerium oxide nanoparticles; Oxidative stress; Nonalcoholic fatty liver disease
dc.description.abstract
Nanopartículas de óxido de cerio; Estrés oxidativo; Enfermedad del hígado graso no alcohólico
dc.description.abstract
Nanopartícules d’òxid de ceri; Estrès oxidatiu; Malalties hepàtiques no alcohòliques
dc.description.abstract
Nonalcoholic fatty liver disease (NAFLD) is characterized by hepatic accumulation of lipids. Antisteatotic effects of cerium oxide nanoparticles (CeO2NPs) have recently been shown in animal models of liver disease. However, it is unclear whether the activity of CeO2NPs is related solely to the decrease in oxidative stress or, in addition, they directly decrease liver fatty acid accumulation. To address this question, in this work, we used an in vitro model of hepatocellular steatosis, exposing HepG2 cells to oleic and palmitic acid. Cell uptake of CeO2NPs and their effect on oxidative stress and viability of hepatic cells cultured with H2O2 were also evaluated. Results show that CeO2NPs were uptaken by HepG2 cells and reduced oxidative stress and improved cell viability. Treatment with oleic and palmitic acid increased lipogenesis and the content of different fatty acids. CeO2NPs reduced palmitic and stearic acid and most fatty acids consisting of more than 18 carbon atoms. These effects were associated with significant changes in elongase and desaturase activity. In conclusion, CeO2NPs directly protected HepG2 cells from cell injury in oxidative stress conditions and reduced fatty acid content in steatotic conditions by inducing specific changes in fatty acid metabolism, thus showing potential in the treatment of NAFLD.
dc.description.abstract
This research was funded by Ministerio de Economía y Competitividad, grant number PI15-00077 to G.C. and SAF2016-75358-R to M.M-R., co-financed by FEDER, European Union, “A way of making Europe”.; “Secretaria d’Universitats i Recerca del Departament d’Empresa i Coneixement de la Generalitat de Catalunya, convocatòria d’Indústria del Coneixement modalitat B”, grant number 2018_PROD_00187 toW.J, cofinanced by the European Union through the European Regional Development Fund (ERDF), “A way of making Europe”.; CIBERehd is financed by the Instituto de Salud Carlos III.;Wuyi University Funding for Hight Talents Introduction, grant number 2018TP010 to E.C. and 2018TP011 to M.Z.; Foundation from Department of Education of Guangdong Province, grant number 2016KCXTD005 and 2017KSYS010, to E.C. and M.Z. The APC was funded by Wuyi University Funding for Hight Talents Introduction, grant number 2018TP010 to E.C.
dc.format
application/pdf
dc.format
application/pdf
dc.language
eng
dc.publisher
MDPI
dc.relation
Biomolecules;9(9)
dc.relation
https://www.mdpi.com/2218-273X/9/9/425
dc.relation
info:eu-repo/grantAgreement/ES/PE2013-2016/PI15-00077
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Scientia
dc.subject
Nanopartícules
dc.subject
Estrès oxidatiu
dc.subject
Esteatosi hepàtica
dc.subject
TECHNOLOGY, INDUSTRY, AND AGRICULTURE::Technology, Industry, and Agriculture::Manufactured Materials::Nanostructures::Nanoparticles::Metal Nanoparticles
dc.subject
PHENOMENA AND PROCESSES::Metabolism::Oxidative Stress
dc.subject
DISEASES::Digestive System Diseases::Liver Diseases::Fatty Liver::Non-alcoholic Fatty Liver Disease
dc.subject
TECNOLOGÍA, INDUSTRIA Y AGRICULTURA::tecnología, industria y agricultura::productos manufacturados::nanoestructuras::nanopartículas::nanopartículas metálicas
dc.subject
FENÓMENOS Y PROCESOS::metabolismo::estrés oxidativo
dc.subject
ENFERMEDADES::enfermedades del sistema digestivo::enfermedades hepáticas::hígado graso::esteatosis hepática no alcohólica
dc.title
Beyond the scavenging of reactive oxygen species (ROS): direct efect of cerium oxide nanoparticles in reducing fatty acids content in an in vitro model of hepatocellular steatosis
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)